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Abstract
Background: The valuable role of immunotherapy in treating autoimmune diseases is increasingly recognized by
those involved in the research and clinical application of new biopharmaceuticals products. However, many aspects
related to the mechanisms of immune-modulated therapies remain to be elucidated in order to explore fully the
emerging opportunities. The non-obese diabetic NOD mouse develops insulin-dependent diabetes mellitus
spontaneously as a consequence of an autoimmune process in the presence of pathogenic CD4+ T cells that
typically exhibit Th17 cell phenotypes. The change of a Th17 phenotype into a pattern of regulatory T cells (Treg) is
extremely important in controlling autoimmune diseases. Heat shock proteins (HSPs) are stress-induced proteins
with immunoregulatory properties. In the current study, the capacity of Hsp65 and Hsp70 mycobacterial HSPs and a
constructed DNA encoded Hsp65 (DNAhsp65) to transform the pattern of the immune response from Th17 into
Treg cells has been studied in vitro using co-cultures of antigen presenting cells (APCs) and T cells in NOD mice.
Results: Cells harvested from NOD mice and cultured for 48 h (without immunoregulatory compounds) presented
with Th1/Th17 patterns and secretions of IL-6, IFN-γ, IL-10 and IL-17 cytokines. The cultured cells from the
non-diabetic BALB/C mice exhibited a Th1 pattern and the production of IL 6 and IFN-γ secretions. An
up-regulation was observed in the supernatants from the co-cultures of NOD cells that were stimulated with
DNAhsp65, Hsp65 or Hsp70 through increased levels of IL-10 secretion and the suppression of IL-6, IFN-γ and IL-17
production. In addition, immunoregulation was demonstrated through IL-17 suppression in the co-culture
stimulated by the specific insulin antigen. Moreover, an increase of immunoregulatory compounds were observed
in the co-culture through the expression of CD11b+CD86+ activation markers on APCs, as well as the frequency of
Treg cells expressing CD4+CD3+ and CD4+CD25hi.
Conclusions: The in vitro observation of Th17 cells differentiating into Tregs in NOD mice could raise the
hypothesis that the immune regulatory activity of HSPs could be an efficient strategy for diabetes prevention and
treatment.
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Background
Diabetes mellitus develops spontaneously in NOD mice
and because of the range of tools and genetic informa-
tion available for mouse studies, the NOD mouse has
become the model of choice for laboratory studies. Stud-
ies using NOD mice have provided a basic understand-
ing of disease mechanisms and immunological tolerance
that have enabled observation and gathering of informa-
tion about the functioning of pathogenic T cells that
would otherwise not been possible without this model.
Insulin-dependent diabetes mellitus is characterized by
increased T cell response toward several auto antigens,
including Hsp60, glutamic acid decarboxylase and insu-
lin [1, 2]. The primary mediators of β-cell destruction
are CD4+ and CD8+ T cells [3, 4]. Pathogenic CD4+ T
cells typically exhibit Th1 and Th17 cell phenotypes,
characterized by increased secretion of several mediators
of the immune response including IFN-γ, TNF-α, IL-6,
IL-10 and IL-17 [5]. Moreover, regulatory T cells (Tregs)
play an important role in the control of autoimmune ill-
nesses, especially in diabetes [6]. Using NOD mice as an
experimental model of diabetes therefore is instrumental
in the pursuit of potential innovative immunotherapies
to treat and resolve insulin-dependent diabetes mellitus.
Heat shock proteins (HSPs) are stress-induced pro-
teins with immunoregulatory properties [7–10]. Immune
responses to HSPs develop in virtually all inflammatory
diseases and the mycobacterial HSPs, mainly Hsp65 and
Hsp70, are known to modulate both the innate and
adaptive host aspects of the immune system [7, 8]. The
mycobacterial Hsp65 as a DNA vaccine construct
(DNAhsp65) has also been the focus of tolerogenic im-
mune interventions aimed at preventing and treating-
mediated diseases such as experimental autoimmune en-
cephalitis, arthritis, atherosclerosis and diabetes [11–14].
Other immunotherapeutic or immunoregulatory effects
of DNAhsp65 were also described by our group for in-
fectious diseases [15], cancer [16], and allergy [17].
We have also shown recently that a DNAhsp65 con-
struct is protective against experimental diabetes in
NOD mice [14]. The protective effect was associated
with a clear shift in the cellular infiltration pattern in the
pancreas. This change included reduction of CD4+ and
CD8+ T cells infiltration, appearance of CD25+ cells in-
flux and an increased staining for interleukin IL-10 in
the islets [14].
In this study, we investigated the ability of Hsp65,
Hsp70 and DNAhsp65 to modify the pattern of immune
response from one that is Th17 to one of Treg cells in a
co-culture of APCs and T cells of NOD mice. We com-
pared the effect of immunoregulatory compounds on
the changes in the production of Th1 and Th17 cyto-
kines by co-cultured cells. Moreover, we analyzed the
changes in the frequency of CD4+ T cells, especially the
CD4+CD25hi Tregs, and the expression of CD11b+CD86
+ activation markers on APCs in co-cultures. Our data
suggest there are an influence of HSPs on the up-
regulation of Tregs in NOD cells based on the changes
in the production of cytokines and the expression of ac-
tivation markers in a co-culture of T cells and antigen
presenting cells (APCs).
Methods
Animals
NOD/Uni mice used in this study derived from the
INSERM U-25 colony at the Hospital Necker (Paris,
France) and had been maintained under germ-free con-
ditions at the animal breeding centre of the State Uni-
versity of Campinas, São Paulo, Brazil. Twenty female
NOD mice were used in the experiments and insulitis
begins around 4 weeks of age and overt hyperglycemia
was observed clearly at around 16 weeks when they were
sacrificed. Female, Specific Pathogen-Free, BALB/c mice
(6–8 weeks old) from the Animal Facility of the Medi-
cine School of Ribeirão Preto, University of São Paulo,
was also used in the experiments.
The animals were maintained on a 12-h light/dark
cycle and given free access to food and autoclaved water.
The experimental protocol was conducted according to
the Ethical Principles In Animal Research adopted by
the Brazilian College of Animal Experimentation
(COBEA) and was approved by the Ribeirão Preto
School of Medicine of University of São Paulo – Ethical
Commission of Ethics in Animal Research (CETEA)
(protocol 042/2011).
Achievement of peritoneal macrophages
Mice were euthanized with an overdose of anesthetic,
ketamine hydrochloride (50 mg/kg) and xylazine
(15 mg/kg). To harvest peritoneal cells, 5 mL of phos-
phate buffered saline were injected (PBS 10 mM, pH: 7.2
at 4 °C) in the peritoneal cavity. Thereafter, the cell solu-
tion was aspirated and transferred to a Falcon tube and
centrifuged at 450 × g for 10 min at 4 °C. After centrifu-
gation, the cell pellet was resuspended in fresh RPMI
medium. The cells were characterized by FACScan using
the following monoclonal antibodies: CD11b-PeCY5
(clone M1/70), CD40-APC (clone 3/23), CD86-PE (clo-
neGL). The percentage of macrophages recovered from
the peritoneal cavity was 58 %. The number of viable cell
concentration was adjusted to 2 × 105cells/mL.
Achievement of splenic cells
After sacrifice and paracentesis, the animals splenectomy
was performed and spleens cells were recovered and
washed twice with RPMI 1640 medium (GIBCO) with-
out added serum and supplemented with 2 mM L-glu-
tamine (Gibco), 1 % 100 mM sodium pyruvate (Gibco),
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2 % non-essential amino acid solution 50 × (GIBCO),
1 % 100× solution of vitamins (GIBCO) and 0.1 % genta-
micin (Novafarma). For these washes, the cells were cen-
trifuged for 8 min at 800 g and 400 g, respectively.
Finally, the cell pellet was resuspended in 10 mL
complete RPMI 1640 medium consisting of 90 % RPMI
1640 medium supplemented as described above and
10 % Fetal Bovine Serum (FBS) (Hyclone). Then the
counting of spleen cells was done in a Neubauer cham-
ber. Differential cell count was promoted in a
hematology analyzer ABX Micros 60® (HORIBA ABX
Diagnostics Inc., Kyoto, Japan).
Separation of CD4+ T lymphocytes
CD4+ and CD8+ T lymphocytes were separated by
negative selection using Magnetic Beads (Stemcell Tech-
nologies Inc., Vancouver, Canada) according to the man-
ufacturer’s instructions. The viability and cell
concentration was performed counting in a Neubauer
chamber with Trypan blue dye. An aliquot of CD3+ cells
recovered after separation with magnetic beads was eval-
uated by flow cytometry to determine the degree of puri-
fication obtained in the separation process. The cells
analyzed by flow cytometry were incubated with specific
monoclonal antibodies (PharMingen, San Diego, USA)
for 30 min at 4 °C. The cells were characterized by
FACScan using the following monoclonal antibodies
were used: CD3–FITC (clone MEL-14), CD4-APC (clone
IM7), CD8–Percp (clone 53–6.7), CD25-PE (clone RM4-
5). After the incubation period, the samples were centri-
fuged at 400 × g for 10 min at 4 °C. The supernatants
poured and samples were washed with 2 mL FACS buf-
fer (PBS plus 2 % FCS) and centrifuged again at 400 × g
for 10 min at 4 °C. At the end of the process, the cells
were fixed with 200 of PBS plus 1 % formaldehyde (JT
Baker, Xalostoc, Mexico). The acquisition of samples
was performed in FACSort (Becton & Dickinson) and
the analysis in Cell Quest program from 25,000 acquired
events. The cell population obtained was selected
through size parameters (FSC) and granularity (SSC)
and within the selected population, the percentage of
cells by double staining was evaluated.
Co-culture of peritoneal macrophages and CD4+ T
lymphocytes
Peritoneal macrophages were distributed into 48 well
culture plates, about 2 × 105 per well in flat bottom
plates (Corning, NY, USA), and resuspended in RPMI
medium supplemented with 10 % fetal bovine serum,
100 U/mL penicillin, 100 ug/mL streptomycin, 100 μg/
mL gentamicin, 2 mM L-glutamine, 50 mM mercap-
toethanol, 1 mM sodium pyruvate. The plates were incu-
bated at 37 °C with an atmosphere of 5 % CO2. After
2 h incubation, the nonadherent cells were removed
gently with cold PBS aid. Approximately 10 × 105 CD4+
T lymphocytes in 500 μL of complete RPMI medium
were added do the cultures.
Co-culture stimulation
In the plates containing macrophages and CD4+ T lym-
phocytes from diabetic NOD or control BALB/c mice
were co-cultured separately in the presence of
DNAhsp65 (50 μg), Hsp65 (5 μg), or Hsp70 (5 μg). As a
negative control, cells were co-cultured only in the pres-
ence of RPMI complete culture medium. As a positive
control, cells were stimulated with Concavalin A (ConA,
40 μg) or insulin (20 μg/mL).
DNAhsp65 and recombinant Hsp65 and Hsp70 proteins
purification
DNA plasmid expressing Hsp65 (DNAhsp65) and the
recombinant mycobacterial Hsp65 and Hsp70 were ob-
tained as previously described [16, 17]. Protein
characterization was performed by electrophoresis on
acrylamide gel developed with 10 % Coomassie Brilliant
Blue R 250 (Ultra Pure). In parallel, it was determined
the protein concentration by the Bradford method
(Comassie® Protein Assay Reagent, Pierce Chemical).
Endotoxin determination
The endotoxin concentrations in samples of recombin-
ant protein and plasmid DNA were determined by LAL
technique using the LAL QCL −1000 kit (Cambrex
Company, Walkersville, MD, USA). The content of
endotoxin in the samples was 0.09 EU endotoxin units/
μg protein. According to FDA specifications, samples
containing values between 0.05 and 0.1 EU endotoxin
units/μg protein are considered appropriate.
Glucose determination
Mice were monitored for the onset of diabetes by mea-
surements of blood glucose using Prestige LX Smart
System test-strips (Home Diagnostic, Inc., Fort Lauder-
dale, FL, USA). Consecutive readings of blood glucose
levels = 200 mg/dL (12 mmol/L) accompanied by glyco-
suria on 2 consecutive days were considered to be diag-
nostic of diabetes onset [13]. The incidence is expressed
as percentages.
Cytokine detection
After the culture period of macrophages and lympho-
cytes for 48 h, with or without stimulus, the culture
plates were centrifuged at 800 g for 10 min. The super-
natants were collected and stored in a freezer at −70 °C
for later titration of cytokines. The determination of the
concentration of IL-6, IL-10, IL-17, and IFN-γ in the
supernatant of the co-cultures was performed by using a
commercial immunoassay kit Milliplex Magpix® Rat/
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Mouse (EMD Millipore Co., Billerica, MA, USA) for
Luminex™ x MAP technology. The fluorescence intensity
was measured and the mean cytokine concentrations
were calculated as pg/mL.
Statistical analysis
All the experimental data are expressed as means ± SEM
and the statistical analyses was performed using the
GraphPadPrism software, version 6.0 (GraphPad Soft-
ware, San Diego, USA). The results were obtained from
three independent experiments. The Student’s t-test was
applied for two-group comparison or one-way ANOVA
with Dunnett’s post-test (medium as reference group)
for multiple comparison. Values of P < 0.05 were consid-
ered statistically significant.
Results
In this work we observed that insulitis in NOD mice be-
gins around 4 weeks of age and overt hyperglycemia was
detected clearly at around 18 weeks and cumulative
insulin-dependent diabetes mellitus incidence reaches
50 % or even more at 22–23 weeks (data not shown). To
evaluate the inflammatory/immune conditions of NOD
mice in comparison with normal non-diabetic BALB/c
mice we first determined the cytokines released in the
supernatants of APCs and CD4+ T cells co-culture. As
shown in Table 1, high levels of IL-6, IL-10, IL-17, and
IFN-γ cytokines were detected in the supernatant of co-
cultures from NOD mice when compared to cells from
BALB/c mice. Contrary to the findings for the cytokines
of NOD mice, the levels of IL-17 and IL-10 were low in
BALB/c mice even under Con-A stimulation. The high
levels of cytokines observed in NOD animal cells with-
out stimulation (media control) may be due to the previ-
ous state of activation of the immune system of these
animals with diabetes when compared with the data ob-
tained from BALB/c mice. These findings show that
antigen specific immune response in diabetic mice is
most commonly associated with Th1/Th17 pattern of
immune response, although insulin also stimulates IL-10
production.
DNAhsp65 and the recombinant Hsp65 and Hsp70
proteins modulate the levels of Th1 and Th17 cytokines
in co-cultures of NOD cells. Indeed, as shown in Fig. 1,
all the compounds down modulated the production of
IL-6 (P < 0.05 for DNAhsp65 and not significantly differ-
ent for Hsp65 and Hsp70), IL-17 (P < 0.001 for
DNAhsp65 and Hsp70 and not significantly different for
Hsp65), and IFN-γ (P < 0.001 for DNAhsp65 and P <
0.05 for Hsp65 and Hsp70). The various treatment con-
ditions also stimulated positively the production of IL-10
(P < 0.05 for Hsp65 and Hsp70 and not significantly dif-
ferent for DNAhsp65). Thus, the suppression of Th1
and Th17 cytokines were clearly detected in the pres-
ence of these compounds indicating that they exhibited
clear immune regulatory activity in co-cultures.
The addition of immunoregulatory compounds in the
co-cultures promotes the activation of APCs and gener-
ation of CD4+CD25hi cells, a hallmark or regulatory T
cells (Treg). Treatment with DNAhsp65, Hsp65 or
Hsp70, in the presence of insulin, caused a significant in-
crease to the expression of the activation marker CD11b
+CD86+ by APCs when compared to those untreated
(Table 2). As for T cells, a significant increase in the fre-
quency of CD4+CD25hi cells, passing from 1.2 ± 0.6
without immunoregulatory to 6.7 ± 1.6, 9.6 ± 3.7 and 7.7
± 1.7 in the presence of DNAhsp65, Hsp65, and Hsp70,
respectively (P < 0.001). As shown in Table 2, the same
pattern was observed for the frequency of cells express-
ing CD4+CD3+ under stimulation with insulin plus
DNAhsp65, Hsp65 or Hsp70 (P < 0.05 compared with
the insulin group).
To further confirm the possible role of HSPs in im-
mune regulation of Th17 cytokine secretion in co-
culture, IL-17 was examined properly. As shown in Fig. 2,
we found that the various treatment conditions sup-
pressed IL-17 secretion (P < 0.001 for Hsp65, P < 0.05 for
DNAhsp65 and not significantly different for Hsp70) in
the supernatants of co-cultures stimulated with the spe-
cific antigen insulin. These data suggest that immuno-
moregulatory compounds might reduce the Th17 cell
population resulting in suppression of IL-17 cytokine
production. Moreover, concomitant with suppression in
Table 1 Analysis of cytokine released (pg/mL) in the supernatant of co-culture of APCs and T lymphocytes from NOD and BALB/c
mice stimulated with medium, Con-A, or insulin
Cytokine Medium Con-A Insulin
NOD BALB/C NOD BALB/C NOD BALB/C
IL-6 6234 ± 3217a 494 ± 377 9660 ± 2001 7632 ± 2104 13,881 ± 1138b 2762 ± 261
IFN-Υ 96 ± 8a 4.5 ± 0.1 4754 ± 1725 3253 ± 3224 480 ± 204a 13 ± 11
IL-17 368 ± 27b 23.6 ± 22 680 ± 219a 28.8 ± 20.7 984 ± 34a 53 ± 26
IL-10 89 ± 12a 1.8 ± 0.5 758 ± 137b 50 ± 35 595 ± 118b 33 ± 21
Data are reported as means ± SD for 3 separate experiments
aP < 0.001
bP < 0.05 when compared BALB/c to NOD mice (t-test)
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Th17, immunoregulatory induced generation of Treg
cells that are important in the control of diabetes with a
concomitant increased level of IL-10 production and de-
creased in IL-6 and IFN-γ.
Discussion
Immunotherapy has made a significant therapeutic im-
pact in immunologically mediated diseases such as can-
cer and allergy, but the search for safe and effective
immunotherapy continues in autoimmune diseases such
as arthritis and diabetes [18, 19]. It has been estimated
that screening experiments of new immunotherapeutic
compounds would require appropriate experimental
model, long time to test and use of large number of ani-
mals. Therefore, it is very important to develop some
strategies for predicting immune regulatory effects of
new compounds in-vitro. NOD mice acquired diabetes
with a characteristic inflammatory Th1 and Th17 pat-
tern of immune response [20–22].
Our study has shown for the first time that T lympho-
cytes obtained from NOD animals exhibit in vitro a pat-
tern profile of Th1 and Th17 when compared to cells
obtained from BALB/c. In particular, IL-6, IFN-gamma,
IL-10 and IL-17 were secreted in the supernatants of co-
cultures of CD4+ T cells and APCs from NOD mice.
γ
Fig. 1 Effect of DNAhsp65, Hsp65 or Hsp70 on IL-6, IFN-γ, IL-10 and IL-17 secretion in co-culture of APCs and CD4+ T cells from NOD mice for
48 h. The levels of cytokines were determined using MilliplexMagpix assay. Data are reported as means ± SD for 3 separate experiments.
*P < 0.001; ** P < 0.05 compared to insulin control (t-test)
Table 2 Analysis of T CD4 lymphocyte expression of CD4+CD3+
and CD4+CD25hi, and CD86 activation markers in APCs
Treatment Percent of cell phenotypes
CD4+CD3+ CD4+CD25hi CD11b+CD86+
Medium 24.5 ± 8.2 0.5 ± 0.2 31.8 ± 7.1
Insulin 34.4 ± 3.8 1.2 ± 0.6 44.8 ± 8.6
Insulin + DNAhsp65 49.2 ± 6.8a 6.7 ± 1.6b 77.6 ± 5.1b
Insulin + Hsp65 42.8 ± 4.5a 9.6 ± 3.7b 69.3 ± 6.0b
Insulin + Hsp70 43.1 ± 3.9a 7.7 ± 1.7b 65.0 ± 7.4b
Data are reported as means ± SD for 3 separate experiments
a P < 0.05 compared to insulin group (t-test)
b P < 0.001
Fig. 2 Effect of DNAhsp65, Hsp65 or Hsp70 on IL-17 secretion in
co-culture of APCs and CD4+ T cells from NOD mice for 48 h in the
presence of insulin. The levels of cytokines were determined using
MilliplexMagpix assay. Data are reported as means ± SD for 3
separate experiments. *P < 0.001; ** P < 0.05 compared to insulin
control (t-test)
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This kind of immune response is consistent with the
previously reported immune response in NOD mice [22]
and these data were used here to evaluate the possible
immune regulatory activity of mycobacterial HSPs in co-
cultures of APCs and T cells.
Hsp65 and Hsp70 proteins and DNAhsp65 have the
ability to modulate co-cultured cells and change a Th1/
Th17 to a Treg pattern of immune response. Although
there was similar pattern of response between all immu-
nomodulators, some small changes occurred that could
be due to the own characteristics of the Hsp65 [7] and
Hsp70 [8] used, as well as for the DNA vaccine con-
struct [23]. The DNA construct must be internalized to
be transcribed and release the Hsp65 protein endogen-
ously [24]. Endogenous Hsp65 can act at different sig-
naling pathways on APCs and T cells in relation to
presented by the exogenous added protein [7]. Hsp65
and Hsp70, when extracellular, are recognized by cellular
immune receptors [7, 8, 25]. The surprising discovery of
HSP receptors on APCs afforded a molecular description
of several immunological mechanisms [7]. Such recogni-
tion allows HSPs to be critical mediators of immune re-
sponses, initiating immune regulatory responses against
cancers or pathogen-infected cells, exacerbating pre-
existing inflammatory conditions, or suppressing on-
going immunity [7].
Hsp65 and Hsp70 can activate rodents and human
macrophages and dendritic cells in vitro [8, 23, 26] and
these early innate responses in turn can be funneled into
and direct the type of adaptive immune response [7].
HSP-stimulated APCs also up-regulate CD80, CD86,
CD40, and MHC class II [7]. We described here an up-
regulation of IL −10 and suppression of IL-17, IL-6 and
IFN-γ by immunomodulators in co-cultures. Note that
the immuneregulatory products induced suppression in
the secretion of IL- 17, both in the presence or absence
of the specific antigen insulin. Moreover there was an
up-regulation of expression of CD11b+CD86+ by APCs
and CD4+CD25hi by T cells. Moreover, there was an in-
crease of T CD4+CD3+ across the stimuli used. This in-
crease may be due to an increase of CD4+ cells
producing IL-10 (Tr1 cells), and this is a point to be in-
vestigated. On the other hand, not necessarily only CD4
+ cells could be CD25hi secreting IL-10. Although not
used antibodies specific for CD4+CD25+Foxp3+ that best
characterizes the Treg cells by FACScan analyses, the
use of CD4+CD25hi markers of T cells in this work also
phenotypically characterizes Treg cells [27–31].
The Th17 lineage of T helper cells can cause severe in-
flammatory diseases and needs to be regulated for their
appropriate control of immune response [32]. It was re-
cently demonstrated that Th17 cells transdifferentiate
into regulatory cells by a change in their signature tran-
scriptional profile and the acquisition of potent
regulatory capacity contributing to the resolution of in-
flammation [32]. In recent years, much evidence has also
been accumulated demonstrating that Treg cells can
suppress auto aggressive T cell responses to host antigen,
both in vitro and in vivo [27–31]. Treg cells were first
described in autoimmune processes where the absence
of CD25+ cells was associated with the development of
autoimmune disease. Mechanisms by which Treg cells
suppress auto aggressive responses are not completely
known. Although cell–cell contact and the production of
anti-inflammatory cytokines, such as IL-10 and TGF-β,
have been implicated [33–35]. Our results are in line
with this hypothesis. Some indications of the protection
afforded by HSPs in various models of experimentally
induced autoimmune diseases include the generation of
Treg cells [7, 8] and the induction of anergy in auto re-
active T cells. Thus, we propose that the presence of
CD4+CD25hi cells, together with the increased levels of
IL-10 in co-cultures of NOD cells, indicate that Treg are
up-regulate in this experimental model. Although not
fully shown in this work, the results suggest that con-
comitant with the appearance of Treg cells, there was a
significant suppression of Th17 lymphocytes, evaluated
by the decrease of IL −17 and IL −6 cytokines in co-
cultures. Evaluations at other time points of co-cultures
with longer follow-up as well as in NOD animals treated
with the immuneregulatory could be valuable to further
investigate the potentially beneficial effects of HSPs in
the immunotherapy of diabetes. These findings provide
import clues to the design of new strategies for using
HSPs in human immunotherapy.
Conclusion
The in vitro model of up-regulation of cells from the im-
mune system described here, showed for the first time
that Hsp65 and Hsp70 proteins and DNAhsp65 have the
ability to modulate co-cultured cells and change a Th1/
Th17 to a Treg pattern of immune response. Thus, this
study shows that immune cells from animals with an
autoimmune disease can be imunoregulated in vitro in
the presence of immunomodulators and open new per-
spectives for using this strategy in the research and de-
velopment of new biopharmaceuticals for controlling
diabetes and others autoimmune diseases, since this
model is safe, effective, fast and easy to develop.
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